|

Visugromab RDE (recommended dose for expansion) Clinical Trials

2 actively recruiting trials across 1 location

No change since May 2026

Also known as: CTL-002

Pipeline

Phase 2: 2

Top Sponsors

  • CatalYm GmbH2

Indications

  • Cancer2
  • Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound1
  • Child-Pugh A Hepatocellular Carcinoma1
  • Unresectable or Metastatic Hepatocellular Carcinoma1
  • Liver Disease1

Other1 trial

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Phase 2

Birmingham, Alabama1 trial

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.